Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $3.75
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| May 5, 26 |
Daily · Wilder smoothing
| Piper Sandler |
| maintain |
| Overweight |
| Overweight |
| Apr 29, 26 | Wedbush | maintain | Outperform | Outperform |
| Mar 31, 26 | Wedbush | maintain | Outperform | Outperform |
| Mar 19, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jan 28, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jan 21, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 20, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jun 25, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 14, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 39.59 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 51.21 | Oscillator | Neutral |
| Williams %R (14) | -46.23 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.42 (Hist 0.07) | Oscillator | Buy |
| Average Directional Index (14) | 41.39 (+DI 16.2 / -DI 27.6) | Trend | Strong Sell |
| EMA 20 | 4.02 | MA | Strong Sell |
| SMA 20 | 3.98 | MA | Strong Sell |
| EMA 50 | 4.66 | MA | Strong Sell |
| SMA 50 | 5.11 | MA | Strong Sell |
| SMA 200 | 4.50 | MA | Strong Sell |
FY2025 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 1, 26 | Kolbeck Roland Wilhelm | officer: Chief Scientific Officer | M-Exempt | 36,375 | — |
| Aug 1, 26 | Kolbeck Roland Wilhelm | officer: Chief Scientific Officer | M-Exempt | 36,375 | — |
| Aug 1, 26 | Kolbeck Roland Wilhelm | officer: Chief Scientific Officer | F-InKind | 12,385 @ $5.20 | $64.40K |
| Jun 5, 26 | Mehra Anand | director | M-Exempt | 11,580 | — |
| Jun 4, 26 | Schiff Andrew N | director | A-Award | 42,350 @ $4.71 | $199.5K |
| Jun 4, 26 | Mehra Anand | director | A-Award | 42,350 @ $4.71 | $199.5K |
| Jun 5, 26 | Schiff Andrew N | director | M-Exempt | 11,580 | — |
| Jun 4, 26 | Mehra Anand | director | A-Award | 10,987 | — |
TTM vs. 5-year historical average (annual ratios)
| Metric | ACRS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -6.5x | -5.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -5.8x | EPS est. -0.65 | In line |
| Price / Book | 4.3x | 2.9x | Elevated |
| Price / Sales | 67.2x | 43.3x | Elevated |
| EV / EBITDA | -7.1x | -6.6x | In line |
| Return on equity | -61.6% | — | Weak |
| Gross margin | 95.6% | 58.1% | Above hist. |
| Debt / Equity | 0.00 | 0.01 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -2.73 | Distress |
Discounted cash flow model
Stock news · updated daily
Here is how Aclaris Therapeutics (ACRS) and Glaukos (GKOS) have performed compared to their sector so far this year.
Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday, September 10, 2026, at 2:45 PM ET, Aclaris' Chief Executive Officer Dr. Neal Walker will participate in a fireside chat during the 2026 Cantor Global Healthcare Conference in New York, NY.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -0.16 | -0.15 | Beat 6.3% | $1.63M |
| May 7, 2026 | -0.16 | -0.15 | Beat 6.3% | $2.00M |
| Feb 26, 2026 | -0.15 | -0.16 | Miss -6.7% | $1.29M |
| Nov 6, 2025 | -0.13 | -0.12 | Beat 7.7% | $3.30M |
| Aug 7, 2025 | -0.13 | -0.13 | Beat 0.0% | $1.78M |
| May 8, 2025 | -0.17 | -0.12 | Beat 29.4% | $1.46M |
| 10-Q | Aug 6, 2026 | 2026-08-06 16:31:14 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 07:15:15 | View |
| 4 | Aug 4, 2026 | 2026-08-04 17:03:20 | View |
| 4 | Jun 8, 2026 | 2026-06-08 16:15:16 | View |
| 4 | Jun 8, 2026 | 2026-06-08 16:15:16 | View |
| 4 | Jun 8, 2026 | 2026-06-08 16:15:14 | View |
Proxy statement (DEF 14A) disclosures